Galapagos Hopes For Third Time Lucky With De-Risked M&A Strategy
The Belgian biotech is closing its CAR-T division and pivoting to a new de-risked business development model, with the blessing of long-term investor, Gilead.
Scrip - January 27, 2026

Boehringer Beefs Up In IBD With Simcere Pact
Deal Snapshot: The German group is the latest big pharma to partner with one of China's most prolific dealmakers in an agreement that could be worth over $1bn.
Scrip - January 27, 2026

Venture Life Lining Up M&A To Cement CHC Focus
Key divestments have given the UK's Venture Life the financial firepower to pursue M&A this year, with a number of options under review across categories such as women's health and energy management.
HBW Insight - January 27, 2026

2026 May Be Decisive For Embedding Self-Care Into Global Health Policy
A new report by Bayer, GSCF and BCIU predicts that 2026 may be pivotal for embedding self?care into global health policy, as progress toward universal healthcare has stalled and urgent, evidence?driven advocacy is needed to ensure self?care becomes a core, scalable component of health systems.
HBW Insight - January 27, 2026

Roche Eyes CT-388 Phase III Trial After Promising Obesity Data
Roche's CT-388 shows promise in Phase II obesity trial but analysts question "commercial relevance" in a crowded market.
Scrip - January 27, 2026

‘The New Default’ – Industry Gives FDA Feedback On Biosimilar Streamlining Guidance
Responding to recent FDA guidance on a new streamlined pathway for US biosimilars, off-patent industry representatives have urged the agency to make the approach “the new default” for biosimilar filings. However, PhRMA has suggested limiting the route to less complex product types.
Generics Bulletin - January 27, 2026

Sun Pharma Lines Up Generic Wegovy As India’s Obesity Drug Market Opens
Sun Pharma’s generic Wegovy product has cleared regulatory review, positioning the company to enter India’s obesity drug market once patent protection lapses.
Generics Bulletin - January 27, 2026

Anticipating 2026 ACC/AHA Guideline Updates That Will Impact The Cardiometabolic Landscape
ACC/AHA guidelines are reshaping US payer policies, expanding coverage and access to breakthrough cardiovascular therapies like SGLT2 and PCSK9 inhibitors. But costs, red tape, and uneven access still stand in the way.
In Vivo - January 27, 2026

New Epidarex $145m Fund Is A Fillip For UK Biotech
Fund IV exclusively targets company creation and early-stage investing across the UK and the US.
Scrip - January 27, 2026

Former Zynex Execs Indicted In $873M Fraud Case
The electrostimulation pain treatment firm reportedly shipped excessive supplies to patients for eight years, driving up revenues as well as stock prices.
Medtech Insight - January 27, 2026

2026 Japan Cell Therapy Landscape: Ventures To Gain Presence With NDAs, IPOs
While several companies await regulatory approval decisions on their cell therapies in Japan, BioCardia proceeds with discussions on an NDA filing and Innovacel readies an IPO.
Scrip - January 27, 2026

Growth Drug In Infant Supplements Adds To US Regulators’ Children’s Health Product Concerns
When FDA warned Agebox about selling iKids-Growth IGF-1 Support supplements as unapproved drugs, agency along with CDC had for around a month been investigating outbreak of infant botulism linked to ByHeart formula.
HBW Insight - January 27, 2026